ArticleCancer immunology, immunotherapy : CII2016

Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2.

Wei Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.